CLL [2016]: Bulletin #3
Gain new key opinion leader (KOL) insights on the latest events that have the potential to shape the treatment landscape of Chronic Lymphocytic Leukaemia (CLL). Coverage includes KOL opinions about the Phase III results published from the GENUINE study investigating TG Therapeutics’ novel anti-CD20 monoclonal antibody (mAb) in combination with J&J/AbbVie’s Imbruvica (ibrutinib). Topics covered include KOL opinions on the approval of Celltrion/Mundipharma biosimilar rituximab (Truxima) by the European Commission. KOLs also provide their candid insights on the sequencing of novel targeted therapies in CLL, availability of real-world data and the future of chemotherapies.
Business Questions
Business Questions
- How do KOLs view the recent Phase III study results of TG Therapeutics’ ublituximab in combination with ibrutinib in the GENUINE trial?
- How do KOLs compare the combination of ibrutinib with ublituximab over the combination of ibrutinib with rituximab and over ibrutinib monotherapy?
- In what type of patients will KOLs use the combination of ublituximab and ibrutinib, if approved?
- Will KOLs require clinical studies to demonstrate the similarity of Truxima to rituximab in CLL? If so, what studies are required?
- How comfortable are KOLs in extrapolating data for the use of Truxima in non-Hodgkin lymphoma (NHL) to CLL?
- Will cost pressures force KOLs to adopt Truxima in patients that require rituximab?
- How will Truxima impact the usage of other anti-CD20 drugs in CLL treatment?
- What are KOL opinions about real-world studies to determine sequencing of treatments in CLL patients? Are there any drawbacks of the current real-world sequencing studies?
- How do KOLs feel about the continued use of chemotherapy in the treatment of patients with CLL?
